**PITX2-dependent gene regulation in atrial fibrillation and rhythm control**

Fahima Syeda¹, Paulus Kirchhof¹,²,³, Larissa Fabritz¹,²,⁴

¹Institute of Cardiovascular Sciences, University of Birmingham, UK
²Department of Cardiology, UHB NHS Trust, Birmingham, UK
³Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany
⁴Department of Cardiovascular Medicine, Division of Rhythmology, University Hospital Münster, Münster, Germany

Corresponding author: Larissa Fabritz

Key words: Pitx2, atrial fibrillation, gene regulation, membrane potential, antiarrhythmic drugs

Abstract:

Atrial fibrillation (AF) is a common arrhythmia. Better prevention and treatment of AF are needed to reduce AF-associated morbidity and mortality. There are several major mechanisms that cause AF in patients, including a genetic predisposition to develop AF. Genome-wide association studies (GWAS) have identified genetic variants associated with AF populations, with the strongest hits clustering on chromosome 4q25, close to the gene for the homeobox transcription factor PITX2. The effect of these common gene variants on cardiac *PITX2* mRNA is currently under study. PITX2 protein regulates right-left differentiation of the embryonic heart, thorax, and aorta. PITX2 is expressed in the adult left atrium, but much less so in other heart chambers. Pitx2 deficiency results in electrical and structural

This is an Accepted Article that has been peer-reviewed and approved for publication in the The Journal of Physiology, but has yet to undergo copy-editing and proof correction. Please cite this article as an 'Accepted Article'; doi: 10.1113/JP273123.

This article is protected by copyright. All rights reserved.
remodeling, and impaired repair of the heart in murine models, all of which may influence AF through divergent mechanisms. *PITX2* levels and SNPs on chromosome 4q25 may also be a predictor of the effectiveness of anti-arrhythmic drug therapy.

Fahima Syeda is a Postdoctoral Research Fellow and Larissa Fabritz is a Reader (Associate Professor) in Cardiovascular Sciences at the Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom. Larissa also sees patients as a Consultant in the Department of Cardiology at University Hospital Birmingham and is affiliated to the University of Muenster, Germany. Fahima gained her BSc at King’s College London and did a PhD in Cardiovascular Physiology at the University of Birmingham, where she studied cardiovascular adaptations to acute and chronic environmental change. Fahima currently uses electrophysiology and imaging techniques to identify mechanisms leading to atrial fibrillation, cardiomyopathies and sudden cardiac death. Our group studies the role of genetic and environmental factors in the development of these diseases and tests interventions in genetic models, helping to delineate new therapeutic targets for personalised treatment.

**Abbreviations**

AF- Atrial fibrillation

GWAS- Genome-wide association studies
miRNA - microRNA

PITX - Paired-like homeodomain transcription factor human and murine protein

PITX - Paired-like homeodomain transcription factor human gene

Pitx - Paired-like homeodomain transcription factor murine gene

SNP - Single nucleotide polymorphism

**Introduction**

Atrial fibrillation (AF) affects two to three percent of the population in Europe and the US and the prevalence of AF is rising (Schnabel et al., 2015; Kirchhof et al., 2016). AF is a significant cause of death, stroke, dementia and reduced quality of life in the Western world and this issue is complicated by a lack of effective therapies. The treatment of AF has four different domains: treatment of underlying cardiovascular conditions, stroke prevention, rate control, and rhythm control. Even on optimal stroke prevention and rate control therapy, cardiovascular morbidity and mortality remains high (Marijon et al., 2013; Bassand et al., 2016). The success of rhythm control therapy is often unpredictable and recurrence is common. This outcome is partly attributable to our limited understanding of the underlying genetic causes of AF and the interaction of these causes with type of rhythm control therapy. Initial observations suggest that the haplotype of common AF-related variants modifies the outcome of antiarrhythmic therapy (Parvez et al., 2012; Huang & Darbar, 2016), suggesting that rhythm control therapy could benefit from precision and personalisation based on genomic information.

**AF has a heritable component**

AF appears to be familial in approximately 15% of early-onset AF without concomitant diseases and 5% of all AF cases (Darbar et al., 2003), and a family history of early-onset AF increases overall AF risk (Fox et al., 2004). Linkage and functional studies have revealed the mutation of several potassium channels such as KCNQ1, KCNE2, KCNH2 in rare, monogenic families with a Mendelian pattern of AF inheritance (Chen et al., 2003; Yang et al., 2004; Hong et al., 2005; Xia et al., 2005). These gain or loss of function potassium channel mutations may account for some of the

This article is protected by copyright. All rights reserved.
electrophysiological changes that promote AF, such as reduced wavelength or early afterdepolarisations, respectively. However, most AF patients do not harbour these rare genotypes with clear phenotypes, so the polygenic and multifactorial nature of AF is an important avenue of research. Therefore, transcriptional regulators with multiple effectors may play a significant role in familial AF caused by common genetic variants.

**Common gene variants associated with AF**

Genome-wide association studies (GWAS), unbiased correlation studies designed to identify associations between allele frequencies and trait variation, have identified multiple loci that associate with AF (Gudbjartsson *et al.*, 2007; Benjamin *et al.*, 2009; Kaab *et al.*, 2009; Ellinor *et al.*, 2010; Schnabel *et al.*, 2011; Ellinor *et al.*, 2012). Initial GWAS identified two single nucleotide polymorphisms (rs2200733 and rs10033464) in European and Chinese populations (Gudbjartsson *et al.*, 2007) on chromosome 4q25. Other loci exist on chromosome 16q22 within intron1 of the gene encoding ZHFX3 i.e. zinc finger homeobox protein 3 (Benjamin *et al.*, 2009) and on chromosome 1q21 on intron 1 of the gene for KCNN3 (involved in calcium-activated potassium channels (Ellinor *et al.*, 2010)). Since these initial studies, a multitude of SNPs that associate with AF have been identified on chromosome 4q25. The gene variants on chromosome 4q25 are intergenic, but many of them are in a genomic “desert” approximately 150kb upstream from the gene for PITX2 (paired-like homeodomain transcription factor).

**The PITX gene family**

The PITX family of homeobox transcription factors consists of PITX1, PITX2 and PITX3, each of which have distinct and overlapping expression patterns, therefore functions, in different organs (Cox *et al.*, 2002). All three members of the PITX family, predominantly PITX2 and PITX3 are expressed in the anterior segment of the eye. In humans, PITX2 mutations are associated with Axenfeld-Rieger syndrome and PITX3 mutations with congenital cataracts (Semina *et al.*, 1998). PITX1 is also essential for hindlimb and pituitary development (Szteto *et al.*, 1999), and PITX2 for tooth, heart, lung, and abdominal development in the mouse (Lin *et al.*, 1999).

Three PITX2 isoforms (PITX2a, PITX2b, and PITX2c), which are generated by alternative splicing and differential promoter usage of the PITX2 gene, are highly expressed in mice and humans during development (Schweickert *et al.*, 2000). The PITX2d isoform, which exists in humans only,
suppresses the transcriptional activity of the PITX2a and PITX2c isoforms (Cox et al., 2002). The predominant cardiac isoform of PITX2 is PITX2c (Kirchhof et al., 2011).

**PITX2 promotes left right asymmetry**

PITX2 was initially described in the context of embryonic development of left-right asymmetry of internal organs: it is expressed in the left heart and gut of the mouse, chick, and xenopus, and its misexpression alters position and the twisting of organs (Ryan et al., 1998; Lin et al., 1999; Campione et al., 2001).

The cardiac system shows left-right asymmetry, e.g. normal coordinated heartbeat is generated from the sinoatrial nodal pacemaker cells in the right atrium. The development of cardiac left-right specific characteristics such as the restriction of the sinoatrial node to the right atrium is critically dependent on asymmetrical organ morphogenesis (Mommersteeg et al., 2007; Galli et al., 2008). Cardiac left-right asymmetry is subject to left-sided PITX2 expression (Galli et al., 2008; Tessari et al., 2008) particularly the PITX2C isoform (Schweickert et al., 2000; Kirchhof et al., 2011) through the lefty-nodal programming pathway (Wang et al., 2010).

**PITX2-dependent gene expression in the adult heart**

Triggered by the GWAS study pointing to a possible role for PITX2 in AF, the role of PITX2 in the adult heart, in addition to its role in left-right asymmetry and cardiac development, has been investigated: Pitx2c expression continues in the postnatal left atrium in mice and humans (Wang et al., 2010; Kahr et al., 2011; Kirchhof et al., 2011) and there is progressive loss of Pitx2c with age in mice (Wang et al., 2010). Thus, Pitx2c dysregulation has the potential to influence AF in adulthood and senescence.

In AF, fast irregular atrial beats overtake the sinoatrial node, sometimes also resulting in ventricular arrhythmias. The origins of ectopic electrical activity are often in the pulmonary veins (Haissaguerre et al., 1998; Po et al., 2005) and if from the left atrium, then predominantly from the left atrial

This article is protected by copyright. All rights reserved.
posterior wall (Sanders et al., 2005; Holmes et al., 2016). Given the crucial role of PITX2 in left-right asymmetry, it is probable that loss of PITX2 in some cases of heritable AF causes incomplete suppression of pacemaker activity in the left heart. This has been shown to be mediated by the loss of Shox2-silencing and increase in Hcn4 (Wang et al., 2010).

**PITX2 mRNA concentrations regulate atrial function**

Both under- and overexpression of PITX2 has been found to be associated with AF (Chinchilla et al., 2011; Perez-Hernandez et al., 2016) in humans. The variability of PITX2 in AF patients suggests that there is a critical level of PITX2 for normal atrial function in the adult. We have recently shown a PITX2 mRNA gradient in AF patients requiring AF ablation. Hence, AF patients could be categorised according to PITX2 levels (Syeda et al., 2016). The mechanisms of AF promotion are diverse, and there are multiple pathways by which PITX2 could regulate arrhythmogenesis. This is unsurprising given that PITX2 is a transcription factor with multiple targets (Hjalt & Semina, 2005). Reduced Pitx2 expression was associated with higher susceptibility to inducible atrial arrhythmias including AF in mice as observed by several groups (Wang et al., 2010; Chinchilla et al., 2011; Kirchhof et al., 2011). Shortened atrial action potential durations, a phenomenon facilitating reentry, were associated with Pitx2 deficiency (Kirchhof et al., 2011).

Postnatal conditional deletion of all Pitx2 isoforms in the left atrium (Pitx2 CKO; achieved by using the muscle creatine kinase-Cre driver) generally resulted in upregulation of genes signifying that, on the whole, PITX2 represses translation. The Pitx2 CKO mouse had irregular resting heart rates and low amplitude P waves (Tao et al., 2014). The upregulation of genes associated with structural remodeling (e.g. integrin alpha 3 and 5) and cell-junction assembly (e.g. desmoplakin and connexin43) indicates that loss of Pitx2 may cause structural remodeling and damage to the intercalated disk (Tao et al., 2014). Prenatal atrial-specific deletion of all Pitx2 isoforms achieved by using a Nppa-Cre driver (NppaCre+Pitx2−/) results in modest atrial enlargement and wall thinning during embryonic development (Chinchilla et al., 2011). Heterozygous deletion of isoform c-specific exon 4 resulting in a 40% reduced left atrial Pitx2c expression (Pitx2c+/−), in contrast, did not cause any obvious structural abnormalities (Kirchhof et al., 2011).

Pitx2 overexpression can promote repair after myocardial injury. So it appears that there is a dynamic Pitx2 response to stress and metabolic changes (Tao et al., 2016). Cis-regulatory elements for the
transcription factor Tbx5 in regions analogous to the human PITX2 risk locus have also been found in the mouse. Postnatal deletion of Tbx5 led to Pitx2 reduction and caused atrial arrhythmias by action potential duration prolongation (Nadadur et al., 2016). Interestingly, inverse relationship between the effects of Tbx5 on some AF-relevant ion channel expression and the effects of Pitx2 on the same ion channels was observed (Tao et al., 2014) and the loss of Pitx2 reversed the pro-arrhythmic effects of the loss of Tbx5 because the loss of either facilitated AF through opposite mechanisms (Nadadur et al., 2016).

Based on several animal models of Pitx2 loss, where haploinsufficiency of Pitx2 has resulted in a less severe phenotype than complete deletion, it can be deduced that there is a dose-dependent regulation of atrial function by Pitx2 in the adult left atrium (Wang et al., 2010; Kirchhof et al., 2011; Lozano-Velasco et al., 2016).

**PITX2-dependent ion channel regulation**

Several potassium channel (Wang et al., 2010; Chinchilla et al., 2011; Kirchhof et al., 2011; Syeda et al., 2016) and calcium handling genes (Tao et al., 2014; Lozano-Velasco et al., 2016) are regulated by Pitx2, as seen in mutant Pitx2 models (Figure 1). The action potential duration shortening observed in Pitx2c−/− mice (Kirchhof et al., 2011) and depolarised resting membrane potential in NppaCre+Pitx2−/− mice and Pitx2c−/− mice suggests that Pitx2 regulates the expression of several potassium channels contributing to atrial repolarisation and to the resting membrane potential. Indeed, in NppaCre+Pitx2−/−, expression of Kcnj2 is decreased (Chinchilla et al., 2011), which would cause a decrease in I_K1, the primary determinant of the resting membrane potential. In Pitx2c−/− mice, both the expression of TASK-2 and TASK-like background currents, contributors to the resting membrane potential, were reduced, though I_K1 was not altered (Syeda et al., 2016).

**Non-protein targets of PITX2**

Multiple microRNAs (miRNAs), short non-coding strands of RNA that usually induce post-transcriptional gene-silencing and fine-tune gene signaling during tissue development and homeostatic control (Beermann et al., 2016), are downstream from Pitx2 and involved in AF.
pathogenesis. *Pitx2* expression co-localises with miR-17-92 cluster expression, and loss of *Pitx2* results in loss of multiple miRNAs that are encoded by miR-17-92 and its closely related homologue miR-106b-25. Mice deficient in these miRNA clusters share similar characteristics to *Pitx2*-deficient mice including induced arrhythmia susceptibility and dysregulation of Shox2 and Tbx3 (Wang et al., 2014). The multiple miRNAs regulated by *Pitx2* may partly explain how *Pitx2* modulates several pathways potentially leading to AF (Li et al., 2016).

**Interactions between SNPs and transcription factors**

Several genes that are either associated with AF in patients who have common intronic or distal variants shown by GWAS or rare variants that directly cause AF as shown by linkage analysis, interact with *PITX2*. These include genes for TBX5 (Huang et al., 2015; Ma et al., 2016; Nadadur et al., 2016), HCN4 (Wang et al., 2010; Mahida & Ellinor, 2012), KCNN3 (Ellinor et al., 2010; Mahida & Ellinor, 2012; Lozano-Velasco et al., 2016), KCNJ2 (Xia et al., 2005; Chinchilla et al., 2011), CAV-1 (Mahida & Ellinor, 2012; Lozano-Velasco et al., 2016) and KCNQ1 (Chen et al., 2003; Wang et al., 2010), as seen in murine models. Thus, *PITX2* potentially regulates AF through several genes already implicated in AF.

It has also been observed that SNPs on different AF susceptibility loci (e.g. rs2200733 on chromosome 4q25 and rs2106261 on chromosome 16q22) interact with each other in AF (Huang et al., 2015) and Zfhx3 has been identified as a possible target for *Pitx2* through CHIP-Seq analysis (Tao et al., 2014). Furthermore, the expression of *Pitx2c* mRNA positively correlates with *ZFHX3* mRNA expression through miR-1 (Huang et al., 2015).

Chromosome conformation capture studies have shown that there is long-range interaction between the risk locus at 4q25 and the *PITX2c* promoter (Aguirre et al., 2015), but beyond this finding, there is little information on how variants distal to *PITX2* interact with *PITX2* to cause AF. Interestingly, an AF-associated SNP proximal to *PITX2* has been shown to regulate *PITX2c* expression in human stem cell-derived cardiomyocytes by regulating *PITX2* enhancer activity (Ye et al., 2016).
Though the interaction between genetic variants close to \textit{PITX2} and \textit{PITX2} itself is not completely understood, the effects of the loss of \textit{PITX2} appear to converge with the presence of AF-associated SNPs.

**The potential to use PITX2 to personalise AF therapy**

Clinical observational studies have suggested that common AF alleles at chromosome 4q25 near \textit{PITX2} modify response to antiarrhythmic therapy in patients (Parvez \textit{et al.}, 2012). Low Pitx2 mRNA also improved the effectiveness of sodium channel blockers in a prospective experimental study (Syeda \textit{et al.}, 2016). \textit{PITX2} levels vary in AF patients (Syeda \textit{et al.}, 2016) and given the observation that loss of left atrial Pitx2 facilitates AF, it may be desirable to target those AF patients who have low \textit{PITX2} as a distinct population for therapy. There is however no clear relation between atrial tissue \textit{PITX2} mRNA levels and SNP haplotype of the common gene variants associated with AF in patients (Gore-Panter \textit{et al.}, 2014; Gore-Panter \textit{et al.}, 2016; Syeda \textit{et al.}, 2016).

The current limited success of rhythm control therapy is thought to be due to heterogeneous drivers causing recurrent AF and modulating treatment response (Fabritz \textit{et al.}, 2016). Amongst the plethora of putative downstream targets of Pitx2, the resting membrane potential (Chinchilla \textit{et al.}, 2011; Syeda \textit{et al.}, 2016) is one that has been seen to be a good predictor of the sodium channel blocking effects of flecainide in isolated cells of human and mouse origin (Syeda \textit{et al.}, 2016). The resting membrane potential is also a good predictor of flecainide’s anti-arrhythmic effectiveness. By using a more precisely targeted approach, these observations of \textit{PITX2} dependent effects may help improve rhythm therapy in the future.

**Open questions regarding research into PITX2:**

1. A robust method for identification of patients with high and low atrial \textit{PITX2} levels is needed. Clearly, measuring \textit{PITX2} expression in atrial tissue of people who are not candidates for surgery is impracticable, so surrogate blood biomarkers of \textit{PITX} could be used to subtype AF patient populations to bring about much-needed leaps in personalised predictions of both AF risk and response to therapy. Currently, the P wave in the ECG still remains the best biomarker for AF (Fabritz, 2016).

This article is protected by copyright. All rights reserved.
2. Well-designed clinical trials to assess PITX2-dependence of the effectiveness of rhythm control therapy could help to reevaluate anti-arrhythmic drugs that have often been ineffective thus far. It is likely that these findings are not limited to PITX2 and the assessment of genotype-dependence on the effectiveness of other anti-arrhythmic drugs could be approached in this manner.

3. Further exploration of the relevance of the resting membrane potential for antiarrhythmic drug therapy success in patients could be valuable.

4. Determination of the major clinical types of AF reflecting different drivers of the arrhythmia – e.g. “early onset AF” as a proxy for genetic predisposition to AF.

5. Characterisation of the interaction of atrial stressors that are often concurrent with AF, with different PITX2 expression levels could also guide the choice of antiarrhythmic drug.

Conclusions

Although the entire scope of the activities and interactions of PITX2 are yet to be elucidated, it is clear that PITX2 has important functions in the adult left atrium and there is evidence in animal models that reduced Pitx2 mRNA levels predispose atria to AF by changing its electrical function, whether by abnormal pacemaker activity or adverse electrical remodeling. While complete deletion of Pitx2 results in structural abnormalities, moderate reduction in atrial Pitx2 levels primarily alters electrical function of the atria, for example the resting membrane potential and ion channel function.

Apparently, AF-associated SNPs on chromosome 4q25 in close proximity to the PITX2 gene do not directly relate to atrial PITX2 mRNA concentrations. Nonetheless, given emerging evidence that PITX2 not only contributes to AF but could be used to predict effectiveness of rhythm control therapy, further investigations into the key co-factors, regulators and targets of PITX2 could change the current strategies used to determine the choice of anti-arrhythmic drugs.

Pitx2 alters the atrial resting membrane potential and thereby modulates the effectiveness of sodium channel blockers in mice. Reliable methods to identify alterations in PITX2 expression in humans may help to make an informed choice on antiarrhythmic drug therapy.

Conflicts of interest

L Fabritz has received institutional research grant support from DFG, MRC, BHF and Gilead Inc. P Kirchhof has received research support from German Centre for Heart Research, from several drug
and device companies active in atrial fibrillation, and has received honoraria from several such companies. F Syeda, L Fabritz, and P Kirchhof are listed as inventors on a patent (WO2015/140571) held by University of Birmingham on genotype-specific antiarrhythmic drug therapy of atrial fibrillation.

**Sources of funding.** This work was supported by European Union (grant agreement No 633193 [CATCH ME] to PK and LF), British Heart Foundation (FS/13/43/30324 to PK and LF), Leducq Foundation to PK

**References**


This article is protected by copyright. All rights reserved.


This article is protected by copyright. All rights reserved.


This article is protected by copyright. All rights reserved.


This article is protected by copyright. All rights reserved.


Abstract figure legend

Figure 1. Reduced Pitx2 expression leads to proarrhythmic electrical remodelling. Several different murine models of Pitx2 downregulation have shown action potential shortening and a depolarised resting membrane, two established causes of arrhythmia. Alterations in calcium and potassium handling genes and TASK-like background currents have been postulated to contribute in different models. The type of electrical remodelling may be a predictor of the anti-arrhythmic effectiveness of rhythm control therapy.